{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:25:00Z","timestamp":1793420700521,"version":"4.5.0"},"reference-count":274,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.neubiorev.2022.104800","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T07:36:59Z","timestamp":1659166619000},"page":"104800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["The opioid system in depression"],"prefix":"10.1016","volume":"140","author":[{"given":"Luke A.","family":"Jelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib1","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41386-018-0136-3","article-title":"The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects","volume":"43","author":"Abdallah","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2007.09.019","article-title":"Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy","volume":"63","author":"Adachi","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib3","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1523\/JNEUROSCI.20-11-04345.2000","article-title":"mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn","volume":"20","author":"Aicher","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.neubiorev.2021.05.003","article-title":"The anterior cingulate cortex as a key locus of ketamine\u2019s antidepressant action","volume":"127","author":"Alexander","year":"2021","journal-title":"Neurosci. Biobehav Rev."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.biopsych.2005.06.036","article-title":"Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments","volume":"59","author":"Alfonso","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib8","first-page":"509","article-title":"Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone","volume":"114","author":"Allolio","year":"1987","journal-title":"Acta Endocrinol."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0269881115586937","article-title":"Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice","volume":"29","author":"Almatroudi","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00213-013-3095-8","article-title":"Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats","volume":"231","author":"Anderson","year":"2014","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2022.104800_bib11","series-title":"Endorphins in Mental Health Research. London %@ 978-1-349-04015-5","first-page":"518","article-title":"Preliminary results of treatment with \u03b2-endorphin in depression","author":"Angst","year":"1979"},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2022.104800_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2006.04.001","article-title":"Stimulation of mitogen-activated protein kinase kinases (MEK1\/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal","volume":"539","author":"Asensio","year":"2006","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-2999(92)90356-9","article-title":"Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation","volume":"216","author":"Baamonde","year":"1992","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0091-3057(02)00961-9","article-title":"Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain","volume":"74","author":"Baker","year":"2002","journal-title":"Pharm. Biochem Behav."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s002100000244","article-title":"Morphine self-administration in mu-opioid receptor-deficient mice","volume":"361","author":"Becker","year":"2000","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib17","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/npp.2014.59","article-title":"Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity","volume":"39","author":"Becker","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"30","key":"10.1016\/j.neubiorev.2022.104800_bib18","doi-asserted-by":"crossref","first-page":"27662","DOI":"10.1074\/jbc.M502593200","article-title":"Mu and kappa opioid receptors activate ERK\/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes","volume":"280","author":"Belcheva","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3182662098","article-title":"Endogenous opioid systems: current concepts and clinical correlations","volume":"79","author":"Benarroch","year":"2012","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.neubiorev.2022.104800_bib20","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2174\/138161209788168100","article-title":"Opiates as antidepressants","volume":"15","author":"Berrocoso","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1461145711001842","article-title":"Active behaviours produced by antidepressants and opioids in the mouse tail suspension test","volume":"16","author":"Berrocoso","year":"2013","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psyneuen.2014.12.004","article-title":"Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans","volume":"52","author":"Bershad","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.dcn.2011.05.001","article-title":"Influence of the OPRM1 gene polymorphism upon children\u2019s degree of withdrawal and brain activation in response to facial expressions","volume":"2","author":"Bertoletti","year":"2012","journal-title":"Dev. Cogn. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02246283","article-title":"Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats","volume":"123","author":"Besson","year":"1996","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1471-4159.2004.02524.x","article-title":"Activation of AP-1 and CRE-dependent gene expression via mu-opioid receptor","volume":"90","author":"Bilecki","year":"2004","journal-title":"J. Neurochem"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.psyneuen.2007.12.010","article-title":"Control of hormonal stress reactivity by the endogenous opioid system","volume":"33","author":"Bilkei-Gorzo","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170348","article-title":"Endogenous Opiates and Behavior: 2018","volume":"132","author":"Bodnar","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.neubiorev.2022.104800_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1476-5381.2009.00230.x","article-title":"Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents","volume":"157","author":"Braida","year":"2009","journal-title":"Br. J. Pharm."},{"issue":"3\u20134","key":"10.1016\/j.neubiorev.2022.104800_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00213-004-1891-x","article-title":"Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys","volume":"176","author":"Broadbear","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1179-y","article-title":"Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats","volume":"164","author":"Broom","year":"2002","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00413-4","article-title":"Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats","volume":"26","author":"Broom","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbr.2014.10.014","article-title":"Antidepressant-like effects of buprenorphine in rats are strain dependent","volume":"278","author":"Browne","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ijnp\/pyx079","article-title":"Reversal of stress-induced social interaction deficits by buprenorphine","volume":"21","author":"Browne","year":"2018","journal-title":"Int J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HRP.0000000000000242","article-title":"Novel targets to treat depression: opioid-based therapeutics","volume":"28","author":"Browne","year":"2020","journal-title":"Harv. Rev. Psychiatry"},{"issue":"43","key":"10.1016\/j.neubiorev.2022.104800_bib37","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1523\/JNEUROSCI.3769-07.2007","article-title":"Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria","volume":"27","author":"Bruchas","year":"2007","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.neubiorev.2022.104800_bib38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/WNR.0b013e32830dd655","article-title":"Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1\/2","volume":"19","author":"Bruchas","year":"2008","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainresrev.2009.09.008","article-title":"kappa-Opioid receptor signaling and brain reward function","volume":"62","author":"Bruijnzeel","year":"2009","journal-title":"Brain Res. Rev."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1364-6613(00)01483-2","article-title":"Cognitive and emotional influences in anterior cingulate cortex","volume":"4","author":"Bush","year":"2000","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.pbr.2018.07.009","article-title":"Potential roles for opioid receptors in motivation and major depressive disorder","volume":"239","author":"Callaghan","year":"2018","journal-title":"Prog. Brain Res"},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress Anxiety"},{"issue":"5397","key":"10.1016\/j.neubiorev.2022.104800_bib43","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1126\/science.282.5397.2272","article-title":"Regulation of cocaine reward by CREB","volume":"282","author":"Carlezon","year":"1998","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","article-title":"The many faces of CREB","volume":"28","author":"Carlezon","year":"2005","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats","volume":"316","author":"Carlezon","year":"2006","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2022.104800_bib46","unstructured":"Chappell P.B. (2002) Effects of CP-122,721, A Selective NK1 Receptor Antagonist, in Patients with MDD. In: NCDEU."},{"key":"10.1016\/j.neubiorev.2022.104800_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","article-title":"It\u2019s MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system","volume":"5","author":"Chartoff","year":"2014","journal-title":"Front Pharm."},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104800_bib48","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuroscience.2014.02.023","article-title":"mu-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain","volume":"267","author":"Chen","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neubiorev.2022.104800_bib50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41380-020-0767-8","article-title":"AP-1 controls the p11-dependent antidepressant response","volume":"25","author":"Chottekalapanda","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.83","article-title":"Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice","volume":"2","author":"Cinque","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J. Pharm. Exp. Ther."},{"issue":"17","key":"10.1016\/j.neubiorev.2022.104800_bib54","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.1523\/JNEUROSCI.22-17-07730.2002","article-title":"Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity","volume":"22","author":"Conley","year":"2002","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib55","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/02698811211044684","article-title":"Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment","volume":"35","author":"Dawson","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.671859","article-title":"REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study","volume":"12","author":"De Martin","year":"2021","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib57","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0022-3565(25)39324-9","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib59","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0269881115584470","article-title":"Polygenic risk scores in imaging genetics: usefulness and applications","volume":"29","author":"Dima","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib60","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/FBP.0000000000000155","article-title":"Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin\/kappa-opioid receptor system","volume":"26","author":"Donahue","year":"2015","journal-title":"Behav. Pharm."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1124\/mol.112.084632","article-title":"Cellular mechanisms of nociceptin\/orphanin FQ (N\/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N\/OFQ","volume":"83","author":"Donica","year":"2013","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0278-5846(01)00161-0","article-title":"Role of endogenous opioid system in the regulation of the stress response","volume":"25","author":"Drolet","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/NDT.S5700","article-title":"Brain-derived neurotrophic factor: role in depression and suicide","volume":"5","author":"Dwivedi","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00726-006-0335-9","article-title":"The role of substance P in stress and anxiety responses","volume":"31","author":"Ebner","year":"2006","journal-title":"Amino Acids"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib66","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrn3231","article-title":"The pain of social disconnection: examining the shared neural underpinnings of physical and social pain","volume":"13","author":"Eisenberger","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib69","first-page":"29","article-title":"Methadone and morphine in depression [proceedings]","volume":"17","author":"Extein","year":"1981","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/syn.20122","article-title":"Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA\/2J and C57BL\/6J mice","volume":"56","author":"Fadda","year":"2005","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib71","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon","year":"2015","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib72","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib73","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib74","first-page":"18","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression","volume":"32","author":"Fava","year":"2020","journal-title":"Ann. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib75","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","article-title":"REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial","volume":"179","author":"Fava","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib77","unstructured":"FDA (2018) Minutes for the November 1, 2018 Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00000542-198204000-00011","article-title":"Opiate receptor mediation of ketamine analgesia","volume":"56","author":"Finck","year":"1982","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib80","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12031-012-9872-8","article-title":"The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress","volume":"50","author":"First","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib82","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pharmthera.2013.05.008","article-title":"Nociceptin\/orphanin FQ receptor antagonists as innovative antidepressant drugs","volume":"140","author":"Gavioli","year":"2013","journal-title":"Pharm. Ther."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib83","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1046\/j.1460-9568.2003.02603.x","article-title":"Blockade of nociceptin\/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test","volume":"17","author":"Gavioli","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib84","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archpsyc.1980.01780190040005","article-title":"beta-Endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients","volume":"37","author":"Gerner","year":"1980","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib85","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1523\/JNEUROSCI.22-03-01146.2002","article-title":"Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors","volume":"22","author":"Ghozland","year":"2002","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","article-title":"The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord","volume":"223","author":"Gorman","year":"1997","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biopsych.2007.07.016","article-title":"Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression","volume":"63","author":"Gourley","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib88","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.111.185108","article-title":"Pharmacological characterization of 2-methyl-N-((2\u2019-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa-opioid receptors","volume":"339","author":"Grimwood","year":"2011","journal-title":"J. Pharm. Exp. Ther."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib89","first-page":"727","article-title":"[Changes and significance of orphanin and serotonin in patients with postpartum depression]","volume":"38","author":"Gu","year":"2003","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib90","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/FBP.0b013e3283586189","article-title":"Antidepressive effects of the kappa-opioid receptor agonist salvinorin A in a rat model of anhedonia","volume":"23","author":"Harden","year":"2012","journal-title":"Behav. Pharm."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib91","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1176\/appi.ajp.161.7.1256","article-title":"Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition","volume":"161","author":"Harmer","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib92","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/0269881110367722","article-title":"Efficacy markers in depression","volume":"25","author":"Harmer","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00441-018-2973-0","article-title":"Animal models of depression: pros and cons","volume":"377","author":"Harro","year":"2019","journal-title":"Cell Tissue Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib95","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib96","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mp.2013.96","article-title":"Response of the mu-opioid system to social rejection and acceptance","volume":"18","author":"Hsu","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/mp.2014.185","article-title":"It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder","volume":"20","author":"Hsu","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","author":"Jacobson","year":"2020","journal-title":"Annu Rev. Pharm. Toxicol."},{"issue":"S1","key":"10.1016\/j.neubiorev.2022.104800_bib99","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2020.34.s1.04214","article-title":"Protracted effects of ketamine require immediate kappa opioid receptor activation and long\u2010lasting desensitization","volume":"34","author":"Jacobson","year":"2020","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib100","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1007\/s00213-020-05649-y","article-title":"The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice","volume":"237","author":"Jacobson","year":"2020","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2022.104800_bib101","first-page":"1","article-title":"Ketamine for depression","author":"Jelen","year":"2021","journal-title":"Int. Rev. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib102","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2021.02.956","article-title":"The roles of endogenous opioid system in the antidepressant actions of ketamine","volume":"89","author":"Jiang","year":"2021","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib104","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.105.088831","article-title":"Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-me thoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats","volume":"315","author":"Jutkiewicz","year":"2005","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib105","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1124\/jpet.105.095810","article-title":"The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol","volume":"317","author":"Jutkiewicz","year":"2006","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104800_bib106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejphar.2005.12.002","article-title":"Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects","volume":"531","author":"Jutkiewicz","year":"2006","journal-title":"Eur. J. Pharm."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib107","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib108","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/j.1460-9568.2004.03581.x","article-title":"Mu-opioid receptor knockout mice show diminished food-anticipatory activity","volume":"20","author":"Kas","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"Suppl 3","key":"10.1016\/j.neubiorev.2022.104800_bib109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0924-9338(02)00651-X","article-title":"A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression","volume":"17","author":"Kasper","year":"2002","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0091-3057(78)90051-5","article-title":"Enkephalin and other peptides reduce passiveness","volume":"9","author":"Kastin","year":"1978","journal-title":"Pharm. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib111","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mp.2016.120","article-title":"HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition","volume":"22","author":"Keller","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib112","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder","volume":"59","author":"Keller","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib113","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/appi.ajp.2007.06091564","article-title":"Association of different adverse life events with distinct patterns of depressive symptoms","volume":"164","author":"Keller","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib114","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.60.8.789","article-title":"Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety","volume":"60","author":"Kendler","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","article-title":"Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women","volume":"63","author":"Kennedy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib116","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.111.091181","article-title":"Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin\/orphanin FQ peptide receptors","volume":"52","author":"Kimura","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib117","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib118","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.1977.01770210125012","article-title":"Beta-endorphin--induced changes in schizophrenic and depressed patients","volume":"34","author":"Kline","year":"1977","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib119","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00000542-200307000-00025","article-title":"Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans","volume":"99","author":"Koppert","year":"2003","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci. Pr. Perspect."},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2022.104800_bib122","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-8993(02)02532-5","article-title":"Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO","volume":"935","author":"Kow","year":"2002","journal-title":"Brain Res."},{"issue":"5383","key":"10.1016\/j.neubiorev.2022.104800_bib123","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.npp.1300260","article-title":"Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression","volume":"29","author":"Kramer","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"103","author":"Kroslak","year":"2007","journal-title":"J. Neurochem."},{"issue":"15","key":"10.1016\/j.neubiorev.2022.104800_bib126","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1073\/pnas.1102693108","article-title":"Social rejection shares somatosensory representations with physical pain","volume":"108","author":"Kross","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib127","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharm. Rep."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib128","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","article-title":"A randomized proof-of-mechanism trial applying the \u2018fast-fail\u2019 approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia","volume":"26","author":"Krystal","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib129","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"issue":"5426","key":"10.1016\/j.neubiorev.2022.104800_bib130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/245447a0","article-title":"Regional distribution of opiate receptor binding in monkey and human brain","volume":"245","author":"Kuhar","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2022.104800_bib131","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.neubiorev.2016.07.002","article-title":"Social functioning in major depressive disorder","volume":"69","author":"Kupferberg","year":"2016","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neubiorev.2022.104800_bib132","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front Psychiatry"},{"issue":"19","key":"10.1016\/j.neubiorev.2022.104800_bib133","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1021\/jm8008986","article-title":"Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4\u2019-piperidine]-4-yl)benzamide (ADL5859)","volume":"51","author":"Le Bourdonnec","year":"2008","journal-title":"J. Med Chem."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib134","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib135","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2010.10.021","article-title":"Deletion of the delta opioid receptor gene impairs place conditioning but preserves morphine reinforcement","volume":"69","author":"Le Merrer","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib136","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4196\/kjpp.2017.21.4.361","article-title":"Effects of tianeptine on symptoms of fibromyalgia via BDNF signaling in a fibromyalgia animal model","volume":"21","author":"Lee","year":"2017","journal-title":"Korean J. Physiol. Pharm."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib137","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","article-title":"Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine","volume":"81","author":"Lener","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib138","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","article-title":"Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures","volume":"111","author":"Lepack","year":"2016","journal-title":"Neuropharmacology"},{"issue":"8091","key":"10.1016\/j.neubiorev.2022.104800_bib139","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0140-6736(78)92762-9","article-title":"The mechanism of placebo analgesia","volume":"2","author":"Levine","year":"1978","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib140","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0026-895X(25)09321-6","article-title":"The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors","volume":"50","author":"Li","year":"1996","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib141","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2967\/jnumed.111.097162","article-title":"Brain and whole-body imaging of nociceptin\/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A","volume":"53","author":"Lohith","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neubiorev.2022.104800_bib142","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroimage.2013.10.068","article-title":"Retest imaging of [11C]NOP-1A binding to nociceptin\/orphanin FQ peptide (NOP) receptors in the brain of healthy humans","volume":"87","author":"Lohith","year":"2014","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib143","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib144","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jnr.24269","article-title":"The opioid system and the social brain: implications for depression and suicide","volume":"98","author":"Lutz","year":"2020","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1098-2396(199609)24:1<19::AID-SYN3>3.0.CO;2-J","article-title":"Imaging of delta opioid receptors in human brain by N1'-([11C]methyl)naltrindole and PET","volume":"24","author":"Madar","year":"1996","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib146","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharm. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib147","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1037\/rev0000033","article-title":"Learned helplessness at fifty: Insights from neuroscience","volume":"123","author":"Maier","year":"2016","journal-title":"Psychol. Rev."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib148","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0891-0618(95)00055-C","article-title":"Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS","volume":"8","author":"Mansour","year":"1995","journal-title":"J. Chem. Neuroanat."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib149","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41386-019-0379-7","article-title":"Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers","volume":"44","author":"Matuskey","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0306-4522(01)00467-5","article-title":"Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus","volume":"109","author":"Maubach","year":"2002","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib151","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"McEwen","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib152","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect Disord."},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104800_bib153","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib154","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","article-title":"Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib155","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2174\/1381612053764779","article-title":"Do substance P and the NK1 receptor have a role in depression and anxiety?","volume":"11","author":"McLean","year":"2005","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22042","article-title":"Kappa opioid receptor binding in major depression: a pilot study","volume":"72","author":"Miller","year":"2018","journal-title":"Synapse"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib157","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"5679","key":"10.1016\/j.neubiorev.2022.104800_bib158","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1126\/science.1095943","article-title":"Deficit in attachment behavior in mice lacking the mu-opioid receptor gene","volume":"304","author":"Moles","year":"2004","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib159","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/0006-3223(90)90619-D","article-title":"Buprenorphine responders","volume":"28","author":"Mongan","year":"1990","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib160","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1523\/JNEUROSCI.5973-10.2011","article-title":"Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats","volume":"31","author":"Muschamp","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib161","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuroimage.2014.05.033","article-title":"Evaluation of the agonist PET radioligand [(1)(1)C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242","volume":"99","author":"Naganawa","year":"2014","journal-title":"Neuroimage"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib162","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2967\/jnumed.114.147975","article-title":"Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the kappa opioid receptor","volume":"56","author":"Naganawa","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib163","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.115.229278","article-title":"Receptor occupancy of the kappa-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050","volume":"356","author":"Naganawa","year":"2016","journal-title":"J. Pharm. Exp. Ther."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib164","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2967\/jnumed.119.227694","article-title":"Kinetic modeling and test-retest reproducibility of (11)C-EKAP and (11)C-FEKAP, novel agonist radiotracers for PET imaging of the kappa-opioid receptor in humans","volume":"61","author":"Naganawa","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104800_bib165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2007.03.031","article-title":"NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action","volume":"566","author":"Naidu","year":"2007","journal-title":"Eur. J. Pharm."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib166","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/(SICI)1096-9861(19991004)412:4<563::AID-CNE2>3.0.CO;2-Z","article-title":"Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding","volume":"412","author":"Neal","year":"1999","journal-title":"J. Comp. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib167","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1176\/appi.ajp.2021.21121204","article-title":"Back to the future: esmethadone, the (maybe) nonopiate opiate, and depression","volume":"179","author":"Nemeroff","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104800_bib168","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2012.04.040","article-title":"The rewarding action of acute cocaine is reduced in beta-endorphin deficient but not in mu opioid receptor knockout mice","volume":"686","author":"Nguyen","year":"2012","journal-title":"Eur. J. Pharm."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104800_bib169","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2012.02.021","article-title":"The role of mu opioid receptors in psychomotor stimulation and conditioned place preference induced by morphine-6-glucuronide","volume":"682","author":"Nguyen","year":"2012","journal-title":"Eur. J. Pharm."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib170","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1523\/JNEUROSCI.16-07-02365.1996","article-title":"Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus","volume":"16","author":"Nibuya","year":"1996","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.neubiorev.2022.104800_bib171","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/bph.13812","article-title":"Opioid system and human emotions","volume":"175","author":"Nummenmaa","year":"2018","journal-title":"Br. J. Pharm."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib172","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41386-020-0725-9","article-title":"Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety","volume":"45","author":"Nummenmaa","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib173","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib174","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clinthera.2012.09.001","article-title":"The economic burden of treatment-resistant depression","volume":"35","author":"Olchanski","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.neubiorev.2022.104800_bib175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and mu- and delta-opioid receptors","volume":"1562","author":"Pacheco Dda","year":"2014","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib176","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib177","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/j.1460-9568.2007.05595.x","article-title":"Decreased motivation to eat in mu-opioid receptor-deficient mice","volume":"25","author":"Papaleo","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"4 Suppl","key":"10.1016\/j.neubiorev.2022.104800_bib178","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1359786806066063","article-title":"The glucocorticoid receptor: part of the solution or part of the problem?","volume":"20","author":"Pariante","year":"2006","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib179","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrn3379","article-title":"Neurotrophin regulation of neural circuit development and function","volume":"14","author":"Park","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib180","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.psyneuen.2008.01.006","article-title":"Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys","volume":"33","author":"Pascoe","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib181","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jcph.1280","article-title":"Abuse potential of buprenorphine\/samidorphan combination compared to buprenorphine and placebo: a phase 1 randomized controlled trial","volume":"59","author":"Pathak","year":"2019","journal-title":"J. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib182","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/mp.2014.164","article-title":"Molecular mechanisms of placebo responses in humans","volume":"20","author":"Pecina","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib183","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamapsychiatry.2015.1335","article-title":"Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression","volume":"72","author":"Pecina","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib184","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/npp.2014.272","article-title":"Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures","volume":"40","author":"Pecina","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41398-018-0263-y","article-title":"Prefrontal expectancy and reinforcement-driven antidepressant placebo effects","volume":"8","author":"Pecina","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib186","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","article-title":"Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches","volume":"24","author":"Pecina","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib187","article-title":"\u03bc opioid antagonist naltrexone partially abolishes the antidepressant placebo effect and reduces orbitofrontal cortex encoding of reinforcement","author":"Pecina","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib188","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0306-4522(98)00251-6","article-title":"Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study","volume":"88","author":"Peckys","year":"1999","journal-title":"Neuroscience"},{"issue":"14","key":"10.1016\/j.neubiorev.2022.104800_bib189","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/bph.13808","article-title":"mu opioid receptor, social behaviour and autism spectrum disorder: reward matters","volume":"175","author":"Pellissier","year":"2018","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2012.01.013","article-title":"Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR","volume":"124","author":"Peng","year":"2012","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib191","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0306-4522(91)90106-X","article-title":"Effects of local delta and mu opioid receptor activation on basal and stimulated dopamine release in striatum and nucleus accumbens of rat: an in vivo electrochemical study","volume":"45","author":"Pentney","year":"1991","journal-title":"Neuroscience"},{"issue":"5560","key":"10.1016\/j.neubiorev.2022.104800_bib192","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.1067176","article-title":"Placebo and opioid analgesia-- imaging a shared neuronal network","volume":"295","author":"Petrovic","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib193","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0006-8993(82)91150-7","article-title":"Opiate receptor binding sites in human brain","volume":"248","author":"Pfeiffer","year":"1982","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib194","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/ajp.138.2.160","article-title":"Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients","volume":"138","author":"Pickar","year":"1981","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib195","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1021\/jm101487v","article-title":"Synthesis and evaluation of radioligands for imaging brain nociceptin\/orphanin FQ peptide (NOP) receptors with positron emission tomography","volume":"54","author":"Pike","year":"2011","journal-title":"J. Med Chem."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib196","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00702-019-02084-y","article-title":"Animal models of major depression: drawbacks and challenges","volume":"126","author":"Planchez","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"18","key":"10.1016\/j.neubiorev.2022.104800_bib197","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1523\/JNEUROSCI.21-18-07397.2001","article-title":"Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens","volume":"21","author":"Pliakas","year":"2001","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104800_bib198","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/npp.2015.348","article-title":"A selective nociceptin receptor antagonist to treat depression: evidence from preclinical and clinical studies","volume":"41","author":"Post","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104800_bib199","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.biopsych.2011.05.021","article-title":"Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity","volume":"70","author":"Potter","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib200","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neubiorev.2019.12.007","article-title":"Opioid receptor modulation of neural circuits in depression: what can be learned from preclinical data?","volume":"108","author":"Puryear","year":"2020","journal-title":"Neurosci. Biobehav Rev."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib201","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.nbd.2008.05.003","article-title":"Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress","volume":"31","author":"Qi","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib202","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1124\/dmd.116.070359","article-title":"Occupancy of nociceptin\/orphanin FQ peptide receptors by the antagonist LY2940094 in rats and healthy human subjects","volume":"44","author":"Raddad","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib203","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00210-001-0511-0","article-title":"Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test","volume":"365","author":"Redrobe","year":"2002","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.neubiorev.2022.104800_bib204","unstructured":"Revixia (2021) Revixia, an atai Life Sciences Company. Available at: https:\/\/www.revixia.life."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib205","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","article-title":"A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression","volume":"233","author":"Richards","year":"2016","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib206","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0022-3565(24)39326-7","article-title":"mu-Opioid receptor knockout mice do not self-administer alcohol","volume":"293","author":"Roberts","year":"2000","journal-title":"J. Pharm. Exp. Ther."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib207","first-page":"1249","article-title":"Increased ethanol self-administration in delta-opioid receptor knockout mice","volume":"25","author":"Roberts","year":"2001","journal-title":"Alcohol Clin. Exp. Res"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib208","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/npp.2011.155","article-title":"The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control","volume":"37","author":"Rodriguez-Munoz","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib209","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0024-3205(02)02220-8","article-title":"Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats","volume":"72","author":"Rojas-Corrales","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib210","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jad.2017.07.042","article-title":"NK1 receptor antagonists for depression: why a validated concept was abandoned","volume":"223","author":"Rupniak","year":"2017","journal-title":"J. Affect Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib212","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/15563650.2020.1781151","article-title":"Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health","volume":"59","author":"Rushton","year":"2021","journal-title":"Clin. Toxicol. (Philos. )"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-2999(78)90217-0","article-title":"Comparative pharmacology of the optical isomers of ketamine in mice","volume":"49","author":"Ryder","year":"1978","journal-title":"Eur. J. Pharm."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib214","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ijnp\/pyaa030","article-title":"Effects of Mu-opiate receptor gene polymorphism rs1799971 (A118G) on the antidepressant and dissociation responses in esketamine nasal spray clinical trials","volume":"23","author":"Saad","year":"2020","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainres.2007.07.095","article-title":"Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-me thoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model","volume":"1208","author":"Saitoh","year":"2008","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib216","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2011.04.041","article-title":"The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions","volume":"223","author":"Saitoh","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104800_bib217","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The behavioral effects of the antidepressant tianeptine require the Mu-opioid receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib218","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00000539-200112000-00031","article-title":"The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception","volume":"93","author":"Sarton","year":"2001","journal-title":"Anesth. Analg."},{"issue":"50","key":"10.1016\/j.neubiorev.2022.104800_bib219","doi-asserted-by":"crossref","first-page":"41595","DOI":"10.1074\/jbc.M112.381368","article-title":"Ligand directed signaling differences between rodent and human kappa-opioid receptors","volume":"287","author":"Schattauer","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib220","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","article-title":"A word to the wise about ketamine","volume":"171","author":"Schatzberg","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib221","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib222","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1038\/npp.2010.114","article-title":"Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models","volume":"35","author":"Schmidt","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib223","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nrn2753","article-title":"A new perspective on the role of the orbitofrontal cortex in adaptive behaviour","volume":"10","author":"Schoenbaum","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib224","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","author":"Sforzini","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib225","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1471-4159.2004.02589.x","article-title":"Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects","volume":"90","author":"Shirayama","year":"2004","journal-title":"J. Neurochem"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib226","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00000542-200110000-00030","article-title":"Activation of mu-opioid receptor induces expression of c-fos and junB via mitogen-activated protein kinase cascade","volume":"95","author":"Shoda","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib227","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.psyneuen.2014.07.009","article-title":"Endogenous opioid system influences depressive reactions to socially painful targeted rejection life events","volume":"49","author":"Slavich","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib228","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib229","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02791072.2018.1438687","article-title":"Tianeptine abuse and dependence in psychiatric patients: a review of 18 case reports in the literature","volume":"50","author":"Springer","year":"2018","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/0261192920939876","article-title":"Some reasons why preclinical studies of psychiatric disorders fail to translate: what can be rescued from the misunderstanding and misuse of animal \u2018models\u2019?","volume":"48","author":"Stanford","year":"2020","journal-title":"Alter. Lab Anim."},{"key":"10.1016\/j.neubiorev.2022.104800_bib231","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1176\/jnp.23.2.jnp121","article-title":"Anterior cingulate cortex: unique role in cognition and emotion","author":"Stevens","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib232","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1111\/j.1460-9568.2007.05952.x","article-title":"Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine","volume":"26","author":"Svenningsson","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib233","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(95)00154-B","article-title":"Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain","volume":"68","author":"Tao","year":"1995","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib234","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/jpet.102.038133","article-title":"GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system","volume":"303","author":"Tao","year":"2002","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1570159X13666150727220944","article-title":"Kappa opioids, salvinorin a and major depressive disorder","volume":"14","author":"Taylor","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib236","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0091-3057(95)00067-7","article-title":"Implication of endogenous opioid system in the learned helplessness model of depression","volume":"52","author":"Tejedor-Real","year":"1995","journal-title":"Pharm. Biochem Behav."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00423-3","article-title":"Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model","volume":"354","author":"Tejedor-Real","year":"1998","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib238","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10550880802122646","article-title":"Psychotherapeutic benefits of opioid agonist therapy","volume":"27","author":"Tenore","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neubiorev.2022.104800_bib239","unstructured":"Therapeutics R. (2021) Relmada Therapeutics announces top-line results of study evaluating REL-1017 vs oxycodone for abuse potential."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib240","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib241","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.npp.1300345","article-title":"The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats","volume":"29","author":"Torregrossa","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib242","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2005.11.005","article-title":"Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats","volume":"1069","author":"Torregrossa","year":"2006","journal-title":"Brain Res."},{"issue":"44","key":"10.1016\/j.neubiorev.2022.104800_bib243","doi-asserted-by":"crossref","first-page":"8778","DOI":"10.1523\/JNEUROSCI.0888-19.2019","article-title":"Toward robust functional neuroimaging genetics of cognition","volume":"39","author":"Udden","year":"2019","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib244","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bjp.0700971","article-title":"The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man","volume":"120","author":"Ur","year":"1997","journal-title":"Br. J. Pharm."},{"issue":"15","key":"10.1016\/j.neubiorev.2022.104800_bib245","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00213-017-4647-0","article-title":"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats","volume":"234","author":"Valenza","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib246","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1749-6632.1982.tb39481.x","article-title":"The effect of codeine on involutional and senile depression","volume":"398","author":"Varga","year":"1982","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib247","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.peptides.2007.10.012","article-title":"Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist","volume":"29","author":"Vergura","year":"2008","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104800_bib248","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-009-1646-9","article-title":"Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N\/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats","volume":"207","author":"Vitale","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104800_bib249","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu Rev. Biochem."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104800_bib250","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s12035-019-1524-3","article-title":"The ERK pathway: molecular mechanisms and treatment of depression","volume":"56","author":"Wang","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"13","key":"10.1016\/j.neubiorev.2022.104800_bib251","first-page":"916","article-title":"[Plasma levels of nociceptin\/orphanin FQ in patients with bipolar disorders and health adults]","volume":"89","author":"Wang","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"35","key":"10.1016\/j.neubiorev.2022.104800_bib252","doi-asserted-by":"crossref","first-page":"15079","DOI":"10.1073\/pnas.0812612106","article-title":"Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection","volume":"106","author":"Way","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib253","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004850-198807000-00007","article-title":"Current and historical concepts of opiate treatment in psychiatric disorders","volume":"3","author":"Weber","year":"1988","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104800_bib254","article-title":"Slaying the dragon: the history of addiction treatment and recovery in America","author":"White","year":"2014","journal-title":"Chestnut Health Syst."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib255","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0306-4530(02)00037-9","article-title":"Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys","volume":"28","author":"Williams","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib256","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104800_bib257","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib258","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/pcn.12042","article-title":"Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy","volume":"67","author":"Woo","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104800_bib259","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fncel.2020.00082","article-title":"The role of BDNF on neural plasticity in depression","volume":"14","author":"Yang","year":"2020","journal-title":"Front Cell Neurosci."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib260","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104800_bib261","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","article-title":"Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial","volume":"173","author":"Yovell","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104800_bib262","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/NDT.S199245","article-title":"Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)","volume":"15","author":"Zajecka","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib263","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.neubiorev.2022.104800_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","author":"Zhang","year":"2021","journal-title":"Pharm. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104800_bib265","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1460-9568.2006.04621.x","article-title":"Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects","volume":"23","author":"Zhang","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104800_bib266","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.05.045","article-title":"Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies","volume":"570","author":"Zhang","year":"2007","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104800_bib267","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"38","key":"10.1016\/j.neubiorev.2022.104800_bib268","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104800_bib269","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.107.039842","article-title":"Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation","volume":"73","author":"Zheng","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neubiorev.2022.104800_bib270","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/bs.pbr.2015.09.001","article-title":"Neuroscience of opiates for addiction medicine: From stress-responsive systems to behavior","volume":"223","author":"Zhou","year":"2016","journal-title":"Prog. Brain Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104800_bib271","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neulet.2005.02.026","article-title":"Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test","volume":"381","author":"Zomkowski","year":"2005","journal-title":"Neurosci. Lett."},{"issue":"5528","key":"10.1016\/j.neubiorev.2022.104800_bib272","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1126\/science.1060952","article-title":"Regional mu opioid receptor regulation of sensory and affective dimensions of pain","volume":"293","author":"Zubieta","year":"2001","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104800_bib273","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archpsyc.60.11.1145","article-title":"Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission","volume":"60","author":"Zubieta","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"34","key":"10.1016\/j.neubiorev.2022.104800_bib274","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1523\/JNEUROSCI.0439-05.2005","article-title":"Placebo effects mediated by endogenous opioid activity on mu-opioid receptors","volume":"25","author":"Zubieta","year":"2005","journal-title":"J. Neurosci."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:20:16Z","timestamp":1758968416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422002895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":274,"alternative-id":["S0149763422002895"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104800","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The opioid system in depression","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104800"}}